Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972678 | 0.87 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL8419513 | 0.87 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL2555602 | 0.85 | GABRA1 (0.56) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL6582792 | 0.83 | CA2 (0.44) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL22542228 | 0.83 | CA2 (0.44) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL28427101 | 0.79 | GABRA1 (0.41) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL28428274 | 0.78 | CA2 (0.40) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL10547937 | 0.76 | ALOX15 (0.46) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL10523675 | 0.75 | CA2 (0.60) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL30772132 | 0.74 | ALDH1A1 (0.50) | CA2GABRA1GABRB2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108250341-B | Catalyst system containing metallocene compound and method for catalyzing olefin polymerization by using catalyst system | 北京引发科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| CN-112147731-B | Optical filter, solid-state imaging device, and camera module | JSR株式会社 | 2023-12-05 | — | — | CN | disclosed |
| US-20230340270-A1 | CYANINE COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-115010837-B | High molecular weight functionalized polyolefin and preparation method thereof | 中国科学院长春应用化学研究所 | 2023-08-25 | — | — | CN | disclosed |
| CN-114874370-B | Ultra-high molecular weight functionalized isotactic polypropylene and preparation method thereof | 中国科学院长春应用化学研究所 | 2023-05-26 | — | — | CN | disclosed |
| CN-113906060-B | Method for producing copolymer | 株式会社普利司通 | 2023-05-09 | — | — | CN | disclosed |
| CN-115010837-A | High molecular weight functionalized polyolefin and preparation method thereof | 中国科学院长春应用化学研究所 | 2022-09-06 | — | — | CN | disclosed |
| CN-114874370-A | Ultrahigh molecular weight functionalized isotactic polypropylene and preparation method thereof | 中国科学院长春应用化学研究所 | 2022-08-09 | — | — | CN | disclosed |
| CN-113906060-A | Method for producing copolymer | 株式会社普利司通 | 2022-01-07 | — | — | CN | disclosed |
| CN-108137756-B | Multipolymer, rubber composition, crosslinked rubber composition, rubber product and tire | 株式会社普利司通 | 2021-06-15 | — | — | CN | disclosed |
| US-6548699-B1 | 4,4*-(Isopropylidenedithio)-(2*,6*-di-tert-butylphenol)-(2,6-d i-tert-butylphenol-O*-acetic acid); antiarthritic, antiinflammatory agents; rheumatic and cardiovascular disorders | ATHEROGENICS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020193446-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-12-19 | — | — | US | disclosed |
| US-20020188118-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-12-12 | — | — | US | disclosed |
| US-20020177717-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020169215-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-11-14 | — | — | US | disclosed |
| US-6147250-A | TREATING DISEASES MEDIATED BY VASCULAR CELL ADHESION MOLECULE-1, INCLUDING CARDIOVASCULAR AND INFLAMMATORY DISEASES; SUCCINOBUCOL | ATHEROGENICS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| CN-1263522-A | Compounds and methods for inhibiting VCAM-1 expression | ATHEROGENICS INC (US) | 2000-08-16 | — | — | CN | disclosed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-3992307-A | BIS-PHOSPHORAMIDE | CHEVRON RESEARCH COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169215-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | CA2 3324/4885GABRA1 1428/4885GABRB2 1782/4885 |
| US-20020193446-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | CA2 3324/4885GABRA1 1428/4885GABRB2 1782/4885 |
| US-20020177717-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | CA2 3324/4885GABRA1 1428/4885GABRB2 1782/4885 |
| US-20020188118-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | CA2 3324/4885GABRA1 1428/4885GABRB2 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.